Tumorgrafts as in vivo surrogates for women with ovarian cancer.
about
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancerEmerging and Evolving Ovarian Cancer Animal ModelsMolecular and clinical implementations of ovarian cancer mouse avatar modelsA novel neutralizing antibody targeting pregnancy-associated plasma protein-a inhibits ovarian cancer growth and ascites accumulation in patient mouse tumorgraftsPrioritizing therapeutic targets using patient-derived xenograft modelsUsing heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancerAdvances in tumor screening, imaging, and avatar technologies for high-grade serous ovarian cancer.Prevention of Human Lymphoproliferative Tumor Formation in Ovarian Cancer Patient-Derived Xenografts.Patient-derived xenograft models in gynecologic malignanciesAn ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancerSpherical cancer models in tumor biology.Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraftQuantitative high throughput screening using a primary human three-dimensional organotypic culture predicts in vivo efficacy.Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes.The promise and challenge of ovarian cancer models.AAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancerBeyond genomics: critical evaluation of cell line utility for ovarian cancer researchBiobanking of patient and patient-derived xenograft ovarian tumour tissue: efficient preservation with low and high fetal calf serum based methodsThe Microbiome and Cancer: Is the 'Oncobiome' Mirage Real?Ovarian carcinoma patient derived xenografts reproduce their tumor of origin and preserve an oligoclonal structureConcomitant loss of SMARCA2 and SMARCA4 expression in small cell carcinoma of the ovary, hypercalcemic typeIt's Totally Tubular....Riding The New Wave of Ovarian Cancer Research.Maternal embryonic leucine zipper kinase serves as a poor prognosis marker and therapeutic target in gastric cancer.Histologic and molecular analysis of patient derived xenografts of high-grade serous ovarian carcinoma.Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer.Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.Functional characterization of a panel of high-grade serous ovarian cancer cell lines as representative experimental models of the diseaseHigh expression of orphan nuclear receptor NR4A1 in a subset of ovarian tumors with worse outcome.A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers.Recent Advances in Understanding, Diagnosing, and Treating Ovarian Cancer.In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma.Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response.Patient-Derived Xenograft Models of Epithelial Ovarian Cancer for Preclinical Studies.Patient-derived xenografts as tools in pharmaceutical development.Active Estrogen Receptor-alpha Signaling in Ovarian Cancer Models and Clinical Specimens.Orthotopic Model of Ovarian Cancer.WNT antagonists exhibit unique combinatorial antitumor activity with taxanes by potentiating mitotic cell death.Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenograftsHuman tissue models in cancer research: looking beyond the mouse.Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors.
P2860
Q26780387-C4944A17-FF7A-431F-A75D-9357E30B4E3CQ26783909-C739264A-262C-4E83-9540-5D2128387A72Q26786724-AB1B3311-5A03-456B-8FC8-7F11395DAF58Q27346392-2BF61A9E-969C-4DA7-AE0A-BD2B7A92FD2BQ28083993-61D49035-0905-4A1B-9C85-D13A5442D4CDQ30409503-C617ED07-E0F2-48DB-9401-22AD3C6A0518Q30423597-2F465F18-E4FB-4D98-B896-0CD3E16BB79AQ33842769-C6D750AA-6F75-49E3-93D8-CF3763B5C1CAQ34141193-2F8FA136-9AD2-4283-926D-8CE0AC2F71B6Q34458291-A261F125-1BC5-44CD-97FA-0CC506115AB7Q35023931-33C43B83-11B9-465F-9F52-0384F38A48D8Q35592388-0FD3D329-1CD7-47E7-A18A-036B39C424B3Q35592860-692F62D7-3157-4E02-A203-34AE3B094C71Q35760892-4E62587D-BBA9-43F3-985B-E263E7982BA5Q35771750-7687536A-1811-4022-B34E-2BC3101F63B0Q35961381-C957CED6-75FB-4865-8E49-85E5FEE68B04Q36104020-51B8E333-6005-4114-9AEB-889F5DFD7869Q36123789-46E289FC-FA55-4196-B7F6-7090ACCE810DQ36272668-BA8C9B2D-EB8F-42E0-9944-040A616602F8Q36414048-DE0F4D01-1A61-4B5A-98D9-478694AD3DB6Q36420683-5BF06519-4D8F-40BC-8F39-D54F9A8EB35DQ36436803-39A0F979-F12A-4E68-8393-2BA4F6FFCC38Q36905898-02BCFEC0-4F26-4289-9063-0467B84AC903Q37272622-F04A83E3-8553-4D7A-82C0-09F402D28029Q37295618-8678661A-2022-4D5A-A3CE-B5A84D3F1FC7Q37353774-373DCA47-4D3D-4184-9481-33BC463DEA4CQ37362776-94CAC723-71AC-4874-9084-2AD14A19524CQ37500390-912D905F-B35D-408C-9581-06DB589EE775Q37558633-04F5EFB6-B613-441D-8C8C-8BB5F2B7B153Q37620476-0607EE82-A02D-4EBB-9E92-AC3980475122Q37726508-837DDA62-124D-4562-A949-D6BB7E74D97DQ38605020-B981E376-1648-457A-B2A9-5C5C9DB8CB38Q38722976-142B22E2-38E9-47D6-AF23-453ED8719AEBQ38732336-12AA38AE-A924-4151-8D0F-4C9C6E86BACCQ39028384-B57AE2C5-919B-4D5A-A1AF-E98E70344467Q39178435-2AF169BD-3838-4EFB-806D-C0190FC6AB60Q41074649-A124E4FB-203D-4994-BB13-6B7B09753F41Q42344756-1D2D140A-1DFB-4DA6-BDC8-C871C9F51945Q42346523-A994F961-31F5-49E0-B14B-33920DFC24EDQ45068320-03D641ED-9EC8-4C00-B8D0-F87F80EE5AA1
P2860
Tumorgrafts as in vivo surrogates for women with ovarian cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Tumorgrafts as in vivo surrogates for women with ovarian cancer.
@en
Tumorgrafts as in vivo surrogates for women with ovarian cancer.
@nl
type
label
Tumorgrafts as in vivo surrogates for women with ovarian cancer.
@en
Tumorgrafts as in vivo surrogates for women with ovarian cancer.
@nl
prefLabel
Tumorgrafts as in vivo surrogates for women with ovarian cancer.
@en
Tumorgrafts as in vivo surrogates for women with ovarian cancer.
@nl
P2093
P2860
P50
P1476
Tumorgrafts as in vivo surrogates for women with ovarian cancer
@en
P2093
Amanika Kumar
Ann L Oberg
Beth Y Karlan
Jann N Sarkaria
Karin M Goodman
Kimberly R Kalli
Kristina A Butler
Lynn C Hartmann
Marc A Becker
Mariam AlHilli
P2860
P304
P356
10.1158/1078-0432.CCR-13-2611
P407
P577
2014-01-07T00:00:00Z